The present situation and plans for the future
10 March 2017
Sanofi Pasteur Canada - who manufactures ImmuCyst™ and licences it to Alliance Pharmaceuticals Ltd for distribution in the UK - has advised BAUS that it has decided to cease the manufacture of ImmuCyst™ from mid-2017. However, Sanofi has stated it expects to be able to continue supply until the end of 2018, and potentially up to mid-2019, depending on the shelf-life of the stock received.
Alliance Pharmaceuticals has written to key prescribers regarding this issue.
Members of the BAUS Section of Oncology are aware of this decision and BAUS is in close contact with Alliance Pharmaceuticals, the Department of Health (DH) , the Medical & Healthcare Products Regulatory Agency (MHRA) , the British Association of Urological Nursing (BAUN) , and the main bladder cancer charities regarding this issue.
The Department of Health (DH) has engaged with Merck Sharp & Dohme (MSD) , as the supplier of the BCG Oncotice™ brand, to make them aware of a potential increase in demand, and to discuss their ability to support the UK market going forward.
View Other News